Clinical Trial Update: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Pfizer conducted a Phase 3 study to evaluate the efficacy and safety of CP-690,550 (tofacitinib) in moderately to severely active ulcerative colitis; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2016-06-01